Page 70 - Haematologica Vol. 109 - July 2024

ARTICLE - Leukemia-induced interferon signature in stroma
M.W.E. Smeets et al.
interferon signaling. J Biol Chem. 2017;292(18):7285-7294.
26. Boukhaled GM, Harding S, Brooks DG. Opposing roles of type I
interferons in cancer immunity. Annu Rev Pathol. 2021;16:167-198.
27. Chmiest D, Sharma N, Zanin N, et al. Spatiotemporal control of 36.
interferon-induced JAK/STAT signalling and gene transcription
by the retromer complex. Nat Commun. 2016;7:13476.
28. Zanin N, Viaris de Lesegno C, Lamaze C, Blouin CM. Interferon
receptor trafficking and signaling: journey to the cross roads. 37.
Front Immunol. 2021;11:615603.
29. Adie EJ, Francis MJ, Davies J, et al. CypHer 5: a generic
approach for measuring the activation and trafficking of G 38. protein-coupled receptors in live cells. Assay Drug Dev Technol. 2003;1(2):251-259. 39.
30. Nath N, Godat B, Zimprich C, et al. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods. 2016;431:11-21.
31. Budhwani M, Mazzieri R, Dolcetti R. Plasticity of type I 40. interferon-mediated responses in cancer therapy: from anti-
tumor immunity to resistance. Front Oncol. 2018;(8):322. 41.
32. Provance OK, Lewis-Wambi J. Deciphering the role of interferon
alpha signaling and microenvironment crosstalk in inflammatory breast cancer. Breast Cancer Res. 2019;21(1):59. 42.
33. Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. 2014;41(2):156-173.
34. Weichselbaum RR, Ishwaran H, Yoon T, et al. An interferon-
related gene signature for DNA damage resistance is a 43. predictive marker for chemotherapy and radiation for breast
cancer. Proc Natl Acad Sci U S A. 2008;105(47):18490-18495.
35. Duarte CW, Willey CD, Zhi D, et al. Expression signature of IFN/
STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 2012;7(1):e29653.
Erdal E, Haider S, Rehwinkel J, Harris AL, McHugh PJ. A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1. Genes Dev. 2017;31(4):353-369.
Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17(9):2619-2627. Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.
Wennerberg E, Pfefferle A, Ekblad L, et al. Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells. Clin Cancer Res. 2014;20(22):5733-5744.
Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174.
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405-414.
Kumar A, Taghi Khani A, Duault C, et al. Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. J Immunother Cancer. 2023;11(5):e006649.
Magenau JM, Peltier D, Riwes M, et al. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021;5(23):5047-5056.
Haematologica | 109 July 2024
2084